List view / Grid view
16 September 2015 | By Victoria White
Findings from the LIRA-LIXI trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in type 2 diabetes...
16 September 2015 | By Victoria White
Nuwiq is the first B-domain deleted recombinant Factor VIII derived from a human cell-line designed for the treatment of patients with haemophilia A...
16 September 2015 | By Victoria White
Moss-aGal, a recombinant form of human alpha galactosidase, is the world´s first moss-produced drug candidate...
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
15 September 2015 | By Victoria White
Data show that Tresiba U200 significantly lowers both rates of hypoglycaemia and mean fasting blood glucose compared to insulin glargine U100 in patients with type 2 diabetes...
15 September 2015 | By Victoria White
The addition of Cannabidiol (CBD)to the medication of patients who were only partially responsive to standard treatment produced significant improvements in outcome measures...
15 September 2015 | By Victoria White
Not only are Saxenda 'early responders' more likely to achieve greater weight loss, they are also more likely to experience greater improvements in cardiometabolic risk factors...
15 September 2015 | By Victoria White
Crucell Holland has been awarded $28.5 million from BARDA to help accelerate the development of its investigational Ebola prime-boost vaccine regimen...
15 September 2015 | By Victoria White
The agreement is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis...
14 September 2015 | By Victoria White
The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study...
14 September 2015 | By Victoria White
A supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) has been submitted to the US Food and Drug Administration (FDA) for front-line use in patients with chronic lymphocytic leukaemia (CLL).
14 September 2015 | By Victoria White
Under the terms of the offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share...
14 September 2015 | By Victoria White
Patients who were treated with increasing doses of resveratrol over 12 months showed little or no change in amyloid-beta40 (Abeta40) levels...
14 September 2015 | By Victoria White
A clinical study demonstratement that ustekinumab can improve psoriasis symptoms and lessen its impact on quality of life in young people aged 12 and over...
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
